Parietal cell

Ocular Therapeutix™ Reports Second Quarter 2021 Financial Results and Business Update

Retrieved on: 
Monday, August 9, 2021
Biotechnology, Health, Pharmaceutical, Optical, Clinical Trials, Intraocular pressure, Compliance, Allergic conjunctivitis, Glaucoma, Webcast, Growth, Review, Prospective payment system, Safety, Marketing, U.S. Securities and Exchange Commission, Duane syndrome, Retina, Ocular hypertension, Software, ASCRS, AMD, COVID-19, Private Securities Litigation Reform Act, Parietal cell, Treatment, Pain, Refractive surgery, CMS, NASDAQ, Wet, Regeneron Pharmaceuticals, Â, Depreciation, OPPS, Eye, Comment, COVID, Security (finance), Resurs Holding, Research, Society, American Society of Cataract and Refractive Surgery, Category 1, International, ID, Sealant, Category, Patient, Investor, Inflammation, Cataract, 3D ultrasound, PDUFA, Axitinib, Company, Prescription Drug User Fee Act, FDA, Clinical trial, IND, Medicare, Pharmaceutical industry, Health insurance, Medical device

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today reported financial results for the second quarter of 2021, and provided updates on its ophthalmology pipeline.

Key Points: 
  • Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today reported financial results for the second quarter of 2021, and provided updates on its ophthalmology pipeline.
  • Net product revenue of DEXTENZA for the quarter was $11.1 million, a nearly 700% increase over the second quarter 2020, and an approximately 65% sequential increase over the first quarter of 2021.
  • Finally, general and administrative expenses were $8.6 million for the second quarter versus $5.1 million in the comparable quarter of 2020.
  • Members of the Ocular Therapeutix management team will host a live conference call and webcast today at 4:30 pm Eastern Time to review the Company's financial results and provide a general business update.

Cinclus Pharma Appoints Jenni Björnulfson as Chief Financial Officer

Retrieved on: 
Thursday, April 16, 2020
Branches of biology, Digestive system, Companies, Medical specialties, AstraZeneca, Gastrin, Gastric acid, Novartis, Parietal cell, Stomach

The Swedish based company Cinclus Pharma Holding AB is the 100% owner of Cinclus Pharma AG, a research-based biotech company, based in Basel, Switzerland.

Key Points: 
  • The Swedish based company Cinclus Pharma Holding AB is the 100% owner of Cinclus Pharma AG, a research-based biotech company, based in Basel, Switzerland.
  • The management team is highly experienced in the GI area (AstraZeneca, Glaxo and Novartis).
  • X842 belongs to the P-CAB class that competitively inhibits the H+, K+-ATPase in the parietal cell and thereby controls gastric acid secretion.
  • X842 is a prodrug of linaprazan, with comprehensive data from 25 Phase I studies including more than 600 subjects.

Cinclus Pharma Appoints Jenni Björnulfson as Chief Financial Officer

Retrieved on: 
Thursday, April 16, 2020
Branches of biology, Digestive system, Companies, Medical specialties, AstraZeneca, Gastrin, Gastric acid, Novartis, Parietal cell, Stomach

The Swedish based company Cinclus Pharma Holding AB is the 100% owner of Cinclus Pharma AG, a research-based biotech company, based in Basel, Switzerland.

Key Points: 
  • The Swedish based company Cinclus Pharma Holding AB is the 100% owner of Cinclus Pharma AG, a research-based biotech company, based in Basel, Switzerland.
  • The management team is highly experienced in the GI area (AstraZeneca, Glaxo and Novartis).
  • X842 belongs to the P-CAB class that competitively inhibits the H+, K+-ATPase in the parietal cell and thereby controls gastric acid secretion.
  • X842 is a prodrug of linaprazan, with comprehensive data from 25 Phase I studies including more than 600 subjects.

Dr. Shaoqing Lai Announces Latest Research on Gastric Cancer

Retrieved on: 
Friday, April 12, 2019
Branches of biology, Medicine, RTT, Abdomen, Medical specialties, Infectious causes of cancer, Stomach, Digestive system, Cancer, Parietal cell, Stomach cancer, Helicobacter pylori

NEW YORK, April 12, 2019 /PRNewswire/ --Today, Scientist Shaoqing Lai announced his latest research on gastric cancer and parietal cell damage.

Key Points: 
  • NEW YORK, April 12, 2019 /PRNewswire/ --Today, Scientist Shaoqing Lai announced his latest research on gastric cancer and parietal cell damage.
  • But scientists are obsessed with the biomedical model and believe that cancer cells are the real killer of cancer disease, killing cancer cells is right way to treat cancer disease.
  • He observed that H.pylori damaged the parietal cells directly and indirectly which led to an increased risk of gastric cancer.
  • In addition to the above, Lai concluded that carcinogenesis of gastric cardiac cancer and distal gastric cancer was the same.